查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1711274

2025年全球核子医学市场报告

Therapeutic Nuclear Drug Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年核医市场规模将快速成长。到 2029 年，这一数字将成长至 38.6 亿美元，复合年增长率为 14.7%。预测期内的增长归因于向个性化医疗的转变、对改善医疗保健基础设施的需求不断增长、老年人口的增加、诊断成像程序的增加以及个性化护理服务的兴起。预测期内的主要趋势包括基于奈米粒子的输送系统、放射性核素治疗的进步、混合成像系统、放射性药物製造和α发射放射性药物的发展以及机器学习和人工智慧的融合。

预计癌症发生率的上升将推动核子治疗市场的成长。癌症的特征是异常细胞不受控制地生长和扩散，由于检测和诊断的改善、生活方式的选择、环境暴露、遗传易感性和其他因素，癌症变得越来越普遍。核子医学在癌症治疗中发挥着至关重要的作用，它透过提供有针对性的有效治疗方法，帮助缩小肿瘤、缓解症状并改善患者的生活品质。例如，2024年2月，总部位于瑞士的联合国机构世界卫生组织（WHO）预测，2050年，全球新诊断癌症病例将超过3,500万例，较2022年预计的2,000万例增加77%。因此，癌症发生率的上升刺激了核子药物市场的扩张。

核子治疗市场的主要企业正在越来越多地建立策略伙伴关係，以加强其竞争地位。这些合作对于加强研发能力、加速新治疗方法的商业化以及透过利用共用资源和专业知识改善来获得创新治疗方法的机会至关重要。例如，2022 年 7 月，德国软体公司 DeepC 与美国人工智慧解决方案供应商 PAIRE 合作，共同推动核医诊断领域的进步。此次合作旨在透过将 PAIRE 的 AI 解决方案 Pionus 整合到 DeepC 的 deepcOS 平台中来提高核医学诊断的准确性和效率，从而增强 PET/ 电脑断层扫描的解释能力。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情景，包括利率、感染疾病、地缘政治、新冠疫情、经济復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 世界核子医学PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球核子医学市场：成长率分析
  • 全球核能药物市场表现：规模与成长，2019-2024
  • 全球核子医学市场预测：2024-2029年及2034年规模与成长
  • 全球核能药物总目标市场（TAM）

第六章市场区隔

  • 全球核子医学市场：依类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 镭223
  • 镏177
  • 碘-131
  • 其他类型
  • 全球核能药物市场：依通路、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 门诊手术中心（ASC）
  • 癌症研究所
  • 全球核子医学市场：依应用、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 甲状腺
  • 骨转移
  • 淋巴瘤
  • 其他用途
  • 全球镭-223核医市场细分（依类型、绩效及预测），2019-2024年，2024-2029年，2034年
  • 摄护腺癌适应症
  • 作用机制
  • 剂型
  • 全球核子治疗药物市场镏177细分市场（按类型、绩效及预测），2019-2024年，2024-2029年，2034年
  • 应用于神经内分泌肿瘤
  • 治疗通讯协定
  • 联合治疗
  • 全球核子治疗市场碘-131细分市场（依类型、绩效及预测），2019-2024年、2024-2029年、2034年
  • 在甲状腺癌的应用
  • 剂量和用法
  • 安全性和有效性
  • 全球核子治疗市场，按类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 额外的治疗同位素
  • 新的治疗方法
  • 研发趋势

第七章 区域和国家分析

  • 全球核子医学市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球核子医学市场：依国家、表现及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 核子治疗市场：竞争格局
  • 核子治疗市场：公司简介
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • Ipsen SA Overview, Products and Services, Strategy and Financial Analysis
    • Jubilant DraxImage Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Mallinckrodt Pharmaceuticals PLC
  • The Bracco Group
  • Lantheus Medical Imaging Inc.
  • Piramal Group
  • Curium Pharmaceuticals
  • Yantai Dongcheng Pharmaceutical Group Co. Ltd.
  • Eckert & Ziegler
  • Telix Pharmaceuticals Limited
  • International Isotopes inc.
  • Orano SA
  • Q BioMed Inc.
  • Molecular Targeting Technologies Inc
  • Medi-Radiopharma Co. Ltd.
  • Actinium Pharmaceuticals
  • Fusion Pharmaceuticals

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年核能药物市场：提供新机会的国家
  • 2029年核子治疗市场：细分领域带来新机会
  • 2029年核子治疗市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r32299

Therapeutic nuclear drugs are medications that use radioactive materials to target and treat diseases, primarily cancer. These drugs employ targeted radiopharmaceuticals that bind to cancer cells and deliver a therapeutic dose of radiation directly to them, aiming to destroy the cancerous cells while minimizing damage to surrounding healthy tissue.

The main types of therapeutic nuclear drugs include radium-223, lutetium-177, iodine-131, and others. Radium-223, for example, is used mainly to treat prostate cancer that has metastasized to the bones. These drugs are distributed through various channels such as hospitals, ambulatory surgical centers, and cancer research institutes, and are utilized in applications like treating thyroid cancer, bone metastases, lymphoma, and other conditions.

The therapeutic nuclear drugs market research report is one of a series of new reports from The Business Research Company that provides therapeutic nuclear drugs market statistics, including the therapeutic nuclear drugs industry global market size, regional shares, competitors with a therapeutic nuclear drugs market share, detailed therapeutic nuclear drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the therapeutic nuclear drugs industry. This therapeutic nuclear drug research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The therapeutic nuclear drug market size has grown rapidly in recent years. It will grow from $1.94 $ billion in 2024 to $2.23 $ billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to increasing regulatory approvals, increasing use of patient-specific information, improving dosimetry techniques, increasing awareness of nuclear medicines and increasing investment in research and development activities.

The therapeutic nuclear drug market size is expected to see rapid growth in the next few years. It will grow to $3.86 $ billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to the shift towards personalized medicine, the rising demand for healthcare infrastructure improvements, the growing geriatric population, the growing number of diagnostic imaging procedures, and the rise of personalized care delivery. Major trends in the forecast period include nanoparticle-based delivery systems, advancements in radionuclide therapy, hybrid imaging systems, radiopharmaceutical manufacturing and development of alpha-emitting radiopharmaceuticals, and integration of machine learning and artificial intelligence.

The rising prevalence of cancer is expected to drive the growth of the therapeutic nuclear drug market. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, is becoming more prevalent due to factors such as improved detection and diagnosis, lifestyle choices, environmental exposures, and genetic predisposition. Therapeutic nuclear drugs play a crucial role in cancer treatment by offering targeted, effective therapies that help reduce tumor size, alleviate symptoms, and improve patients' quality of life. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based UN agency, projected that over 35 million new cancer cases will be diagnosed by 2050, marking a 77% increase from the estimated 20 million cases in 2022. As a result, the growing prevalence of cancer is fueling the expansion of the therapeutic nuclear drug market.

Major companies in the therapeutic nuclear drug market are increasingly forming strategic partnerships to strengthen their competitive position. These collaborations are crucial for enhancing research and development capabilities, speeding up the commercialization of new therapies, and improving access to innovative treatments by leveraging shared resources and expertise. For example, in July 2022, DeepC, a Germany-based software company, partnered with PAIRE, a U.S.-based AI solutions provider, to advance nuclear medicine diagnostics. Through this partnership, they aim to improve the precision and efficiency of nuclear medicine diagnostics by integrating PAIRE's AI solution, Pionus, into DeepC's deepcOS platform, which enhances the interpretation of PET/CT scans.

In May 2024, Telix Pharmaceuticals Limited, an Australian biotechnology company, acquired QSAM Biosciences for an undisclosed amount. This acquisition aims to bolster Telix's therapeutic pipeline with the investigational drug Samarium-153-DOTMP, which targets bone metastases and osteosarcoma. QSAM Biosciences, a US-based biotech firm, specializes in developing next-generation nuclear therapeutic medicines.

Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals

North America was the largest region in the therapeutic nuclear drug market in 2023. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the therapeutic nuclear drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The therapeutic nuclear drug market consists of sales of yttrium-90, actinium-225, bismuth-213, therapeutic iodine-123, and copper-67. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Therapeutic Nuclear Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on therapeutic nuclear drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for therapeutic nuclear drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The therapeutic nuclear drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Radium-223; Lutetium-177; Iodine-131; Other Types
  • 2) By Distribution Channel: Hospitals; Ambulatory Surgical Centers (ASCs); Cancer Research Institutes
  • 3) By Application: Thyroid; Bone Metastasis; Lymphoma; Other Applications
  • Subsegments:
  • 1) Radium-223: Indications for prostate cancer; Mechanism of action; Dosage forms
  • 2) Lutetium-177: Applications in neuroendocrine tumors; Treatment protocols; Combination therapies
  • 3) Iodine-131: Use in thyroid cancer; Dosage and administration; Safety and efficacy
  • 4) Other Types: Additional therapeutic isotopes; Emerging treatments; Research and development trends
  • Companies Mentioned: Bayer AG; Novartis International AG; Siemens Healthineers AG; Ipsen S.A.; Jubilant DraxImage Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Therapeutic Nuclear Drug Market Characteristics

3. Therapeutic Nuclear Drug Market Trends And Strategies

4. Therapeutic Nuclear Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Therapeutic Nuclear Drug Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Therapeutic Nuclear Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Therapeutic Nuclear Drug Market Growth Rate Analysis
  • 5.4. Global Therapeutic Nuclear Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Therapeutic Nuclear Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Therapeutic Nuclear Drug Total Addressable Market (TAM)

6. Therapeutic Nuclear Drug Market Segmentation

  • 6.1. Global Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Radium-223
  • Lutetium-177
  • Iodine-131
  • Other Types
  • 6.2. Global Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Cancer Research Institutes
  • 6.3. Global Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Thyroid
  • Bone Metastasis
  • Lymphoma
  • Other Applications
  • 6.4. Global Therapeutic Nuclear Drug Market, Sub-Segmentation Of Radium-223, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Prostate Cancer Indications
  • Mechanism of Action
  • Dosage Forms
  • 6.5. Global Therapeutic Nuclear Drug Market, Sub-Segmentation Of Lutetium-177, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Applications in Neuroendocrine Tumors
  • Treatment Protocols
  • Combination Therapies
  • 6.6. Global Therapeutic Nuclear Drug Market, Sub-Segmentation Of Iodine-131, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Use in Thyroid Cancer
  • Dosage and Administration
  • Safety and Efficacy
  • 6.7. Global Therapeutic Nuclear Drug Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Additional Therapeutic Isotopes
  • Emerging Treatments
  • Research and Development Trends

7. Therapeutic Nuclear Drug Market Regional And Country Analysis

  • 7.1. Global Therapeutic Nuclear Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Therapeutic Nuclear Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Therapeutic Nuclear Drug Market

  • 8.1. Asia-Pacific Therapeutic Nuclear Drug Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Therapeutic Nuclear Drug Market

  • 9.1. China Therapeutic Nuclear Drug Market Overview
  • 9.2. China Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Therapeutic Nuclear Drug Market

  • 10.1. India Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Therapeutic Nuclear Drug Market

  • 11.1. Japan Therapeutic Nuclear Drug Market Overview
  • 11.2. Japan Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Therapeutic Nuclear Drug Market

  • 12.1. Australia Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Therapeutic Nuclear Drug Market

  • 13.1. Indonesia Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Therapeutic Nuclear Drug Market

  • 14.1. South Korea Therapeutic Nuclear Drug Market Overview
  • 14.2. South Korea Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Therapeutic Nuclear Drug Market

  • 15.1. Western Europe Therapeutic Nuclear Drug Market Overview
  • 15.2. Western Europe Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Therapeutic Nuclear Drug Market

  • 16.1. UK Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Therapeutic Nuclear Drug Market

  • 17.1. Germany Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Therapeutic Nuclear Drug Market

  • 18.1. France Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Therapeutic Nuclear Drug Market

  • 19.1. Italy Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Therapeutic Nuclear Drug Market

  • 20.1. Spain Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Therapeutic Nuclear Drug Market

  • 21.1. Eastern Europe Therapeutic Nuclear Drug Market Overview
  • 21.2. Eastern Europe Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Therapeutic Nuclear Drug Market

  • 22.1. Russia Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Therapeutic Nuclear Drug Market

  • 23.1. North America Therapeutic Nuclear Drug Market Overview
  • 23.2. North America Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Therapeutic Nuclear Drug Market

  • 24.1. USA Therapeutic Nuclear Drug Market Overview
  • 24.2. USA Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Therapeutic Nuclear Drug Market

  • 25.1. Canada Therapeutic Nuclear Drug Market Overview
  • 25.2. Canada Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Therapeutic Nuclear Drug Market

  • 26.1. South America Therapeutic Nuclear Drug Market Overview
  • 26.2. South America Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Therapeutic Nuclear Drug Market

  • 27.1. Brazil Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Therapeutic Nuclear Drug Market

  • 28.1. Middle East Therapeutic Nuclear Drug Market Overview
  • 28.2. Middle East Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Therapeutic Nuclear Drug Market

  • 29.1. Africa Therapeutic Nuclear Drug Market Overview
  • 29.2. Africa Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Therapeutic Nuclear Drug Market Competitive Landscape And Company Profiles

  • 30.1. Therapeutic Nuclear Drug Market Competitive Landscape
  • 30.2. Therapeutic Nuclear Drug Market Company Profiles
    • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Ipsen S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Jubilant DraxImage Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Therapeutic Nuclear Drug Market Other Major And Innovative Companies

  • 31.1. Mallinckrodt Pharmaceuticals PLC
  • 31.2. The Bracco Group
  • 31.3. Lantheus Medical Imaging Inc.
  • 31.4. Piramal Group
  • 31.5. Curium Pharmaceuticals
  • 31.6. Yantai Dongcheng Pharmaceutical Group Co. Ltd.
  • 31.7. Eckert & Ziegler
  • 31.8. Telix Pharmaceuticals Limited
  • 31.9. International Isotopes inc.
  • 31.10. Orano SA
  • 31.11. Q BioMed Inc.
  • 31.12. Molecular Targeting Technologies Inc
  • 31.13. Medi-Radiopharma Co. Ltd.
  • 31.14. Actinium Pharmaceuticals
  • 31.15. Fusion Pharmaceuticals

32. Global Therapeutic Nuclear Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Therapeutic Nuclear Drug Market

34. Recent Developments In The Therapeutic Nuclear Drug Market

35. Therapeutic Nuclear Drug Market High Potential Countries, Segments and Strategies

  • 35.1 Therapeutic Nuclear Drug Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Therapeutic Nuclear Drug Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Therapeutic Nuclear Drug Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer